Delusional disorder is defined by fixed delusions with relatively preserved overall functioning, whereas schizophrenia involves a broader set of psychotic symptoms. In schizophrenia you typically see perceptual disturbances (prominent hallucinations), disorganized thinking that disrupts speech, disorganized or abnormal behavior, and negative symptoms like flat affect or avolition, often with some cognitive impairment. The absence of those prominent, wide-ranging psychotic features is what distinguishes delusional disorder from schizophrenia. Mood disturbances can occur in both, and cognitive decline is more characteristic of other conditions, but the defining difference here is that delusional disorder lacks the prominent hallucinations, disorganized speech, and negative symptoms that define schizophrenia.

Dosing captopril in this context is about starting with a very low, tolerable amount to begin ACE inhibition while monitoring the patient’s response and safety. The plan specifies a small daily amount, 12.5 mg, which fits a cautious approach to avoid first-dose hypotension and to allow gradual adjustment. Higher daily doses, such as 50 mg or 100 mg, would carry greater risk of adverse effects and aren’t what this plan uses. A dose as low as 2.5 mg/day is typically insufficient to achieve meaningful ACE inhibition. So, 12.5 mg/day is the best match to the management plan described.

Lamotrigine is cleared mainly through glucuronidation by UDP-glucuronosyltransferase (UGT) enzymes, especially UGT1A4. This glucuronidation pathway is where most clinically relevant interactions occur—most notably with valproic acid, which inhibits UGT-mediated glucuronidation and raises lamotrigine levels, increasing the risk of serious rash. The CYP450 system, P-glycoprotein, and SLC transporters are not the primary routes for lamotrigine metabolism, so interactions via those pathways are less expected.

Thrombocytopenia can be a rare adverse effect of several antipsychotics, reflecting idiosyncratic or immune-mediated destruction of platelets. Among these medications, multiple second-generation (atypical) antipsychotics have documented reports of thrombocytopenia, including asenapine, clozapine, olanzapine, quetiapine, risperidone, and ziprasidone. This breadth is why this set is the best answer: it captures the class-wide potential for this hematologic reaction, based on clinical reports and pharmacovigilance data. In practice, if a patient on these drugs develops signs of bleeding or petechiae, or has unexpectedly low platelets on a CBC, clinicians should evaluate the platelets and consider the antipsychotic as a contributing factor, balancing risks and benefits and monitoring accordingly. Clozapine, in particular, is well known for hematologic risks and requires regular monitoring for neutropenia, while other antipsychotics may present thrombocytopenia less predictably but have documented associations.